MaxCyte IPO Presentation Deck
Value Creation from SPLs
Licensing deals include significant development
milestones and high-value participation in future
commercial success of partners
Potential value of pre-commercial (clinical
development) milestones from SPLs exceeds
$950m USD
Sales-based payments upon partner's product
commercialization
July 2021
Recurring revenues from lease of instruments and
sales of single-use disposables that grow with
program success
Milestone revenue is MaxCyte's highest growth
tit revenue stream
M MaxCyte
2016
CONFIDENTIAL
Cumulative Potential Pre-CML Milestones
2017
CASEBIA
THERAPEUTICS
2018
CRISPR
Beam
PRECISION
2019
>$950m USD
editas
KSQ
Kite
APEIRON
VOR
2020
CO
celularity
MYELCID
CARIBOU
BIOSCIENCES
Allogene
BIOLOGICS
2021View entire presentation